As of Feb 27
| +0.03 / +0.31%|
The 5 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 12.50, with a high estimate of 14.00 and a low estimate of 5.00. The median estimate represents a +27.81% increase from the last price of 9.78.
The current consensus among 5 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.